SWP
VKTX icon

ShoreHaven Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

ShoreHaven Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,495
Closed -$9K – 246
2021
Q1 		$9K Hold
1,495
– – ﹤0.01% 202
2020
Q4 		$8K Buy
+1,495
New +$9.06K ﹤0.01% 183

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ShoreHaven Wealth Partners's VKTX Position: Q2 2021 in Review

ShoreHaven Wealth Partners sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 1,495 shares — an estimated $9K sold.

ShoreHaven Wealth Partners first reported a position in VKTX in Q4 2020 and held it in 2 quarters. The position peaked at $9K in Q1 2021. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

  • ShoreHaven Wealth Partners reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ShoreHaven Wealth Partners sold 1,495 Viking Therapeutics shares in Q2 2021, an estimated $9K.
  • ShoreHaven Wealth Partners first reported a position in Viking Therapeutics in Q4 2020 and held it in 2 quarters.
  • ShoreHaven Wealth Partners's Viking Therapeutics position peaked at $9K in Q1 2021.
  • 138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on ShoreHaven Wealth Partners's 13F filing for Q2 2021, filed 16 Aug 2021.